source
- Axsome receives FDA nod for Alzheimer’s agitation treatmentAxsome announced that the U.S. Food and Drug Administration granted it a nod for a therapy aimed at agitation associated with Alzheimer’s disease, according to the STAT+ report. The decision marks…
- FDA proposes removing obesity and diabetes drug ingredients from compounding substances listThe U.S. Food and Drug Administration has issued a proposal to remove the active ingredients of widely used obesity and diabetes medicines from the list of substances that can be compounded. The ch…